---
title: 'Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis
  of a phase 3b, open-label trial'
date: '2023-12-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38127586/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231222170702&v=2.18.0
source: Blood
description: Subcutaneous emicizumab enables prophylaxis for people with hemophilia
  A (HA) from birth, potentially reducing risk of bleeding and intracranial hemorrhage
  (ICH). HAVEN 7 (NCT04431726) is the first clinical trial of emicizumab dedicated
  to infants, designed to investigate the efficacy, safety, pharmacokinetics, and
  pharmacodynamics of emicizumab in those ≤12 months of age with severe HA without
  factor (F)VIII inhibitors. Participants in this phase 3b trial received emicizumab
  3 mg/kg ...
disable_comments: true
---
Subcutaneous emicizumab enables prophylaxis for people with hemophilia A (HA) from birth, potentially reducing risk of bleeding and intracranial hemorrhage (ICH). HAVEN 7 (NCT04431726) is the first clinical trial of emicizumab dedicated to infants, designed to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in those ≤12 months of age with severe HA without factor (F)VIII inhibitors. Participants in this phase 3b trial received emicizumab 3 mg/kg ...